Humana surges: Barclays bets big on Medicare star ratings rebound

Humana (HUM) stock rose 8% after Barclays upgraded it to Overweight from Equalweight, indicating a more positive outlook. The stock has seen significant volatility, with an 8-month low of -20.6% due to CMS payment rate concerns. Humana is up 54.3% YTD, near its 52-week high. Investors who bought shares 5 years ago have seen modest gains.

Humana's stock rose 6.2% after Barclays upgraded it to Overweight and raised its price target to $515. The firm cited confidence in Humana's turnaround and Medicare Advantage improvements. Management reaffirmed 2026 EPS guidance of at least $9.00. The S&P 500, Dow Jones, and Nasdaq also saw modest gains.

Humana (HUM) shares rose 7% to $406.42 after Barclays upgraded it to Overweight and set a $515 price target. UnitedHealth (UNH) gained 0.7%. Humana's YTD gain is now 60%, driven by analyst sentiment. The move is isolated, with no sector-wide impact.

Humana Inc. shares rose 7.9% to $410.30 after Barclays upgraded the stock to Overweight and increased its price target to $515 from $407, citing growth potential. The company's market cap is $49.4 billion. The upgrade follows strong Medicare Advantage enrollment and reimbursement trends. Humana's stock saw high trading volume, reflecting investor interest in healthcare stocks.

Humana (HUM) and HealthStream (HSTM) partnered to expand caregiver training. Humana reported Q2 2026 adjusted EPS of $7.61, lowering FY GAAP EPS guidance to $6.52. HealthStream saw Q2 revenue rise 12.5% to $83.7M, with net income up 23.8%. Humana faces regulatory pressures, while HealthStream benefits from strong margins and a debt-free balance sheet.

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.